Insider Selling: Disc Medicine (NASDAQ:IRON) Insider Sells $486,062.64 in Stock

Disc Medicine, Inc. (NASDAQ:IRON) insider William Jacob Savage sold 7,378 shares of the company’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $65.88, for a total transaction of $486,062.64. Following the transaction, the insider owned 85,211 shares in the company, valued at approximately $5,613,700.68. This trade represents a 7.97% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

William Jacob Savage also recently made the following trade(s):

• On Tuesday, February 17th, William Jacob Savage sold 3,256 shares of Disc Medicine stock. The stock was sold at an average price of $62.86, for a total transaction of $204,672.16.
• On Monday, December 15th, William Jacob Savage sold 13,093 shares of Disc Medicine stock. The shares were sold at an average price of $91.22, for a total value of $1,194,343.46.

Disc Medicine Price Performance

NASDAQ:IRON opened at $61.18 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 21.94 and a quick ratio of 23.45. The company has a 50 day moving average price of $72.69 and a 200-day moving average price of $75.50. Disc Medicine, Inc. has a 1-year low of $30.82 and a 1-year high of $99.50. The firm has a market cap of $2.31 billion, a price-to-earnings ratio of -10.21 and a beta of 0.87.

Disc Medicine (NASDAQ:IRON) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($1.62) EPS for the quarter, topping the consensus estimate of ($1.69) by $0.07. The company had revenue of ($19.88) million during the quarter, compared to analysts’ expectations of $0.15 million. Equities research analysts forecast that Disc Medicine, Inc. will post -4.07 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. ANTIPODES PARTNERS Ltd purchased a new stake in Disc Medicine in the 4th quarter valued at approximately $33,000. Aster Capital Management DIFC Ltd acquired a new stake in shares of Disc Medicine in the third quarter valued at about $38,000. CWM LLC lifted its stake in shares of Disc Medicine by 213.5% in the second quarter. CWM LLC now owns 1,044 shares of the company’s stock valued at $55,000 after purchasing an additional 711 shares during the period. KBC Group NV purchased a new stake in Disc Medicine during the fourth quarter worth about $80,000. Finally, Avanza Fonder AB boosted its holdings in Disc Medicine by 54.0% during the third quarter. Avanza Fonder AB now owns 1,668 shares of the company’s stock worth $110,000 after buying an additional 585 shares in the last quarter. 83.70% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have recently commented on IRON shares. Wells Fargo & Company raised their price target on Disc Medicine from $78.00 to $79.00 and gave the stock an “overweight” rating in a research report on Monday, March 2nd. Wedbush decreased their target price on Disc Medicine from $110.00 to $88.00 and set an “outperform” rating on the stock in a research note on Tuesday, February 17th. Raymond James Financial restated a “market perform” rating on shares of Disc Medicine in a report on Thursday, January 15th. Stifel Nicolaus cut their price target on shares of Disc Medicine from $125.00 to $110.00 and set a “buy” rating on the stock in a research note on Tuesday, February 17th. Finally, Cantor Fitzgerald reduced their price target on shares of Disc Medicine from $153.00 to $125.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 17th. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Disc Medicine presently has a consensus rating of “Moderate Buy” and a consensus target price of $104.80.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.